Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2a plus adefovir or tenofovir versus no treatment in HBeAg-negative chronic hepatitis B with low viral load
NL-OMON32978Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of interferon alfa, adefovir dipivoxil and tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Primary efficacy endpoint. Started Sep 2009; status: active, not recruiting.
02
Drugs
interferon alfaadefovir dipivoxiltenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON32978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32978.